About Zilia

Dominic has an extensive experience working for the development of new technologies in industrial and academic environments for applications in biotechnology and bioengineering. He is associate Professor in the Department of Chemical and Materials Engineering at the University of Alberta, Dominic has a strong background and expertise in academic and industrial bioengineering.

Claude is an experienced leader and entrepreneur with 30+ years of experience in life sciences including clinical research, product development, sales, marketing, operations and business development. Claude also worked in the venture capital sector, playing a major role in the financing of numerous ventures.

Dominique is a certified Ophthalmologist and founder of a renowned private medical center. As an active clinical researcher in the field of ophthalmology, she provides valuable knowledge and insight into the development and application of Zilia’s technology.

Danny is a pharmacist-owner since 2002 and President of Gilbert Gobeil Martel Pharmacies, which is comprised of four pharmacies and 125 employees. Over the years, Danny has built a strong expertise in marketing, sales and business operations. He is also an active private investor in the healthcare sector.

Dr. Ahmed is a leader in novel treatments for glaucoma, cataract, and lens implant surgery. His pioneering work in glaucoma surgery includes developing micro-invasive glaucoma surgery (MIGS). An assistant professor at the University of Toronto and a professor at the University of Utah, he is also a research director at the Kensington Eye Institute and director of the Glaucoma and Advanced Anterior Segment Surgery (GAASS) fellowship, both at the University of Toronto. In addition, Dr. Ahmed is head of the ophthalmology division at Trillium Health Partners. He is recognized as one of the most experienced complex eye surgeons in the world.

Dr. Rajat N Agrawal is President and CEO of Retina Global, a not-for-profit organization addressing retinal diseases in underserved areas of the world, an Adjunct Professor at the Roski Eye Institute, and a Visiting Professor at the Dept. of Ophthalmology at the University of Southern California. He is a world-renowned ophthalmologist and retina specialist. He has been involved in developing a number of medical devices, including the ARGUS-II which allows some blind patients to see again, and drugs for the treatment of ocular diseases. He holds a Masters in Regulatory Affairs and works as a consultant for pre-clinical and clinical research, and business and market evaluation. He has been an advisor for investments and acquisitions of early to late-stage biomed opportunities, totaling over 50 million dollars.

John G. Flanagan is the Dean and Professor at School of Optometry and Vision Science Program, University of California, Berkeley. Dr. Flanagan graduated in Optometry and Vision Sciences from Aston University, Birmingham, UK in 1980, where he later earned his PhD in 1985. During his career, he has received a multitude of honors for his work including the Certificate of Merit for Research Excellence (Glaucoma Research Society of Canada), the Glenn A Fry Award (American Academy of Optometry), and more recently, the President’s Award for services to the profession of optometry (American Optometric Association). He has supervised 45 graduate students and has authored over 175 peer-reviewed publications. In addition, he has 14 book chapters, 3 books and has given numerous invited lectures primarily focusing on ocular imaging to ocular blood flow and vascular reactivity.

Eric is a biomedical engineer with over 20 years of experience in developing and commercializing medical devices and biomedical applications. He is a guest professor at École Polytechnique and ÉTS.